JP2020516594A - ナノメディシンにおける受容体リガンド相互作用の効力を測定するためのアッセイ - Google Patents

ナノメディシンにおける受容体リガンド相互作用の効力を測定するためのアッセイ Download PDF

Info

Publication number
JP2020516594A
JP2020516594A JP2019554417A JP2019554417A JP2020516594A JP 2020516594 A JP2020516594 A JP 2020516594A JP 2019554417 A JP2019554417 A JP 2019554417A JP 2019554417 A JP2019554417 A JP 2019554417A JP 2020516594 A JP2020516594 A JP 2020516594A
Authority
JP
Japan
Prior art keywords
antigen
cell
disease
cells
antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019554417A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020516594A5 (https=
Inventor
サンタマリア，ペドロ
Original Assignee
ユーティーアイ リミテッド パートナーシップ
ユーティーアイ リミテッド パートナーシップ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユーティーアイ リミテッド パートナーシップ, ユーティーアイ リミテッド パートナーシップ filed Critical ユーティーアイ リミテッド パートナーシップ
Publication of JP2020516594A publication Critical patent/JP2020516594A/ja
Publication of JP2020516594A5 publication Critical patent/JP2020516594A5/ja
Priority to JP2024024899A priority Critical patent/JP2024073459A/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90241—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Nanotechnology (AREA)
JP2019554417A 2017-04-07 2018-04-05 ナノメディシンにおける受容体リガンド相互作用の効力を測定するためのアッセイ Pending JP2020516594A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024024899A JP2024073459A (ja) 2017-04-07 2024-02-21 ナノメディシンにおける受容体リガンド相互作用の効力を測定するためのアッセイ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762483298P 2017-04-07 2017-04-07
US62/483,298 2017-04-07
PCT/IB2018/000510 WO2018185564A2 (en) 2017-04-07 2018-04-05 Assay to measure the potency of receptor-ligand interactions in nanomedicines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024024899A Division JP2024073459A (ja) 2017-04-07 2024-02-21 ナノメディシンにおける受容体リガンド相互作用の効力を測定するためのアッセイ

Publications (2)

Publication Number Publication Date
JP2020516594A true JP2020516594A (ja) 2020-06-11
JP2020516594A5 JP2020516594A5 (https=) 2021-05-13

Family

ID=63713282

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019554417A Pending JP2020516594A (ja) 2017-04-07 2018-04-05 ナノメディシンにおける受容体リガンド相互作用の効力を測定するためのアッセイ
JP2024024899A Pending JP2024073459A (ja) 2017-04-07 2024-02-21 ナノメディシンにおける受容体リガンド相互作用の効力を測定するためのアッセイ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024024899A Pending JP2024073459A (ja) 2017-04-07 2024-02-21 ナノメディシンにおける受容体リガンド相互作用の効力を測定するためのアッセイ

Country Status (13)

Country Link
US (2) US20200057048A1 (https=)
EP (1) EP3607058A4 (https=)
JP (2) JP2020516594A (https=)
KR (1) KR20200004807A (https=)
CN (1) CN110945120B (https=)
AU (1) AU2018248961B2 (https=)
BR (1) BR112019021022A2 (https=)
CO (1) CO2019011018A2 (https=)
IL (1) IL269846A (https=)
MX (1) MX2019012058A (https=)
RU (1) RU2019135533A (https=)
SG (1) SG11201909290TA (https=)
WO (1) WO2018185564A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024248042A1 (ja) * 2023-05-29 2024-12-05 国立大学法人 東京大学 ＭｕＳＫを標的とする新規化合物及びその用途

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
SG10201803780UA (en) 2013-11-04 2018-06-28 Uti Lp Methods and compositions for sustained immunotherapy
ES3055030T3 (en) 2015-05-06 2026-02-09 Uti Lp Nanoparticle compositions for sustained therapy
EP3716949A4 (en) 2017-11-29 2022-05-18 UTI Limited Partnership Methods of treating autoimmune disease
CN112585162B (zh) * 2018-08-06 2025-01-28 基因医疗免疫疗法有限责任公司 Ha-1特异性t细胞受体及其用途
GB201906127D0 (en) * 2019-05-01 2019-06-12 Immutep S A Assays
EP3958892A4 (en) * 2019-05-23 2023-06-14 UTI Limited Partnership METHOD OF TREATMENT OF LIVER DISEASE
KR20220150276A (ko) * 2020-01-11 2022-11-10 시벡 바이오테크놀로지스, 엘엘씨 진핵생물로의 진핵생물-번역가능한 mRNA의 생산 및 전달을 위한 미생물 시스템
CN115917654A (zh) * 2020-04-21 2023-04-04 瑞泽恩制药公司 用于分析受体相互作用的方法和系统
WO2021148683A2 (en) * 2020-05-06 2021-07-29 Imcyse Sa Peptides and methods for the treatment of multiple sclerosis
TW202208395A (zh) 2020-05-12 2022-03-01 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
EP4211149A4 (en) * 2020-09-09 2024-10-09 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF
CA3232037A1 (en) * 2021-09-21 2023-03-30 Monash University Methods of treatment
CN113960003B (zh) * 2021-10-20 2023-10-24 吉林大学 基于dna银纳米簇和金纳米棒检测四环素的适配体传感器
US11873507B2 (en) * 2021-11-29 2024-01-16 Replicate Bioscience, Inc. Compositions and methods for expression of IL-12 and IL-1RA
EP4249062A1 (en) * 2022-03-24 2023-09-27 Julius-Maximilians-Universität Würzburg Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo
CN115125205A (zh) * 2022-06-14 2022-09-30 中国医学科学院生物医学工程研究所 一种修饰EpCAM抗体和/或CSV抗体的白细胞磁球及其制备方法
AU2024346292A1 (en) * 2023-09-22 2026-04-02 Julius-Maximilians-Universität Würzburg, In Vertretung Des Freistaates Bayern Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006016113A1 (en) * 2004-08-12 2006-02-16 Avidex Ltd. Cellular tcr ligand assay method
JP2010522695A (ja) * 2007-03-07 2010-07-08 ユーティーアイ リミテッド パートナーシップ 自己免疫状態の予防および治療のための組成物および方法
JP2015503354A (ja) * 2012-01-04 2015-02-02 レイセオン ビービーエヌ テクノロジーズ コーポレイション 調節分子−遺伝子エレメント対により提示される遺伝子発現レベルを評価する方法
WO2016081854A1 (en) * 2014-11-20 2016-05-26 Promega Corporation Systems and methods for assessing modulators of immune checkpoints
WO2016193299A1 (en) * 2015-06-01 2016-12-08 Medigene Immunotherapies Gmbh T cell receptor library
WO2016198932A2 (en) * 2015-05-06 2016-12-15 Uti Limited Partnership Nanoparticle compositions for sustained therapy
JP2018531593A (ja) * 2015-09-11 2018-11-01 アジェナス インコーポレイテッド 操作された宿主細胞及びそれらの使用方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US707993A (en) 1901-05-16 1902-08-26 Clinton J Warren Machine for corking bottles.
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US6103379A (en) 1994-10-06 2000-08-15 Bar-Ilan University Process for the preparation of microspheres and microspheres made thereby
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6924123B2 (en) 1996-10-29 2005-08-02 Oxford Biomedica (Uk) Limited Lentiviral LTR-deleted vector
AU3896699A (en) 1998-05-07 1999-11-23 Regents Of The University Of California, The Use of neglected target tissue antigens in modulation of immune responses
US6150022A (en) 1998-12-07 2000-11-21 Flex Products, Inc. Bright metal flake based pigments
US7419829B2 (en) 2000-10-06 2008-09-02 Oxford Biomedica (Uk) Limited Vector system
KR100379250B1 (ko) 2000-12-04 2003-04-08 한국과학기술연구원 나노 단위 크기의 금속 입자가 함유된 고분자 복합 소재및 그 제조 방법
DE60226852D1 (de) 2001-03-13 2008-07-10 Novartis Ag Lentivirale verpackungskonstrukte
WO2009027978A1 (en) 2007-08-30 2009-03-05 Hadasit Medical Research Services & Development Ltd. NUCLEIC ACID SEQUENCES COMPRISING NF-ϰB BINDING SITE WITHIN O(6)-METHYLGUANINE-DNA-METHYLTRANSFERASE (MGMT) PROMOTER REGION AND USES THEREOF FOR THE TREATMENT OF CANCER AND IMMUNE-RELATED DISORDERS
WO2010055510A2 (en) 2008-11-12 2010-05-20 Yeda Research And Development Co. Ltd. Diagnosis of multiple sclerosis
CA2777053A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
CA2813064C (en) 2010-09-29 2021-06-01 Uti Limited Partnership Methods for treating autoimmune disease using biocompatible bioabsorbable nanospheres
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
JP6014440B2 (ja) 2012-09-26 2016-10-25 日立オートモティブシステムズ株式会社 移動物体認識装置
SG10201803780UA (en) 2013-11-04 2018-06-28 Uti Lp Methods and compositions for sustained immunotherapy
EP3233903B1 (en) * 2014-12-19 2020-12-09 ETH Zürich Chimeric antigen receptors and methods of use
EP3067366A1 (en) * 2015-03-13 2016-09-14 Max-Delbrück-Centrum Für Molekulare Medizin Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1
KR20260048600A (ko) * 2015-03-27 2026-04-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 변형된 t 세포 및 이의 제조 및 사용 방법

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006016113A1 (en) * 2004-08-12 2006-02-16 Avidex Ltd. Cellular tcr ligand assay method
JP2010522695A (ja) * 2007-03-07 2010-07-08 ユーティーアイ リミテッド パートナーシップ 自己免疫状態の予防および治療のための組成物および方法
JP2015503354A (ja) * 2012-01-04 2015-02-02 レイセオン ビービーエヌ テクノロジーズ コーポレイション 調節分子−遺伝子エレメント対により提示される遺伝子発現レベルを評価する方法
WO2016081854A1 (en) * 2014-11-20 2016-05-26 Promega Corporation Systems and methods for assessing modulators of immune checkpoints
WO2016198932A2 (en) * 2015-05-06 2016-12-15 Uti Limited Partnership Nanoparticle compositions for sustained therapy
WO2016193299A1 (en) * 2015-06-01 2016-12-08 Medigene Immunotherapies Gmbh T cell receptor library
JP2018531593A (ja) * 2015-09-11 2018-11-01 アジェナス インコーポレイテッド 操作された宿主細胞及びそれらの使用方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"T cell receptor alpha chain [Homo sapiens](ACCESSION:AAC14923)", NCBIホームページ, vol. VERSION:AAC14923.1, JPN6022011465, 27 April 1998 (1998-04-27), ISSN: 0005101770 *
"T cell receptor beta chain [Homo sapiens]（ACCESSION：AAC08954）", NCBIホームページ, vol. VERSION：AAC08954.1, JPN6022011466, 2 November 2001 (2001-11-02), ISSN: 0005101771 *
ACS NANO, vol. 9, no. 1, JPN6022011463, 2015, pages 16 - 30, ISSN: 0005101769 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024248042A1 (ja) * 2023-05-29 2024-12-05 国立大学法人 東京大学 ＭｕＳＫを標的とする新規化合物及びその用途

Also Published As

Publication number Publication date
US20240201171A1 (en) 2024-06-20
BR112019021022A2 (pt) 2020-06-09
SG11201909290TA (en) 2019-11-28
CN110945120A (zh) 2020-03-31
AU2018248961A1 (en) 2019-10-31
MX2019012058A (es) 2019-11-11
WO2018185564A2 (en) 2018-10-11
AU2018248961B2 (en) 2024-06-20
WO2018185564A3 (en) 2019-01-03
EP3607058A4 (en) 2020-12-16
CA3059016A1 (en) 2018-10-11
KR20200004807A (ko) 2020-01-14
JP2024073459A (ja) 2024-05-29
IL269846A (en) 2019-11-28
RU2019135533A (ru) 2021-05-07
US20200057048A1 (en) 2020-02-20
CO2019011018A2 (es) 2019-10-21
CN110945120B (zh) 2025-04-18
EP3607058A2 (en) 2020-02-12

Similar Documents

Publication Publication Date Title
US20240201171A1 (en) Assay to measure the potency of receptor-ligand interactions in nanomedicines
US20240299536A1 (en) Nanoparticle compositions for sustained therapy
US20250019406A1 (en) Sorting with counter selection using sequence similar peptides
JP2023055758A (ja) 同種異系腫瘍細胞ワクチン
KR20200064085A (ko) 접합 부위를 갖는 t-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
US20200352999A1 (en) Use and production of engineered immune cells to disrupt nfat-ap1 pathway transcription factors
Middelburg et al. The MHC-E peptide ligands for checkpoint CD94/NKG2A are governed by inflammatory signals, whereas LILRB1/2 receptors are peptide indifferent
CA3059016C (en) Assay to measure the potency of receptor-ligand interactions in nanomedicines
US20240358831A1 (en) Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange
WO2025021979A1 (en) Novel t cell receptors targeting melanoma-associated antigen (mage) b2 and immune therapy using the same
CA3191448A1 (en) Alloreactive immune cell-distancing device and uses thereof for protecting donor-derived cells from allorejection
HK1252348B (en) Nanoparticle compositions for sustained therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210330

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210330

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220324

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220620

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230118

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20230404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230404

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230706

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231023